Skip to content
BiologicalX

Comparison

Hexarelin vs Omega-3 (EPA/DHA)

Side-by-side of Hexarelin and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Hexarelin

  • Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
  • Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
  • Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
  • More cortisol and prolactin elevation than GHRP-2 or ipamorelin
  • Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
  • Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Side-by-side

Attribute Hexarelin Omega-3 (EPA/DHA)
Category peptide supplement
Also known as Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 fish oil, EPA, DHA, marine omega-3
Half-life (hr) 1 48
Typical dose (mg) 0.1 2000
Dosing frequency 1-2x daily 1 to 2 times daily with food
Routes subcutaneous, intranasal, intravenous oral
Onset (hr) 0.25 4
Peak (hr) 0.5 12
Molecular weight 887.04 302.45
Molecular formula C47H58N12O6 C20H30O2 (EPA); C22H32O2 (DHA)
Mechanism Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function.
Legal status Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia
WADA status banned allowed
DEA / Rx Not scheduled (research chemical) Not scheduled
Pregnancy Insufficient data; not recommended Recommended at 200 to 600 mg DHA/day for fetal development
CAS 140703-51-1 10417-94-4
PubChem CID 3037387 446284
Wikidata Q5743550 Q207688

Safety profile

Hexarelin

Common side effects

  • water retention
  • vivid dreams
  • head pressure or flushing
  • transient lethargy
  • tingling at injection site
  • moderate hunger

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • prolactin-sensitive states

Interactions

  • CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: amplify cortisol load; blunt GH response(moderate)

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.

  • If your priority is growth-hormone axis, pick Hexarelin.
  • If your priority is post-training recovery, pick Hexarelin.
  • If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
  • If your priority is healthspan extension, pick Omega-3 (EPA/DHA).

Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Hexarelin and Omega-3 (EPA/DHA)?

Hexarelin and Omega-3 (EPA/DHA) differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Hexarelin or Omega-3 (EPA/DHA)?

Hexarelin half-life is 1 hours; Omega-3 (EPA/DHA) half-life is 48 hours.

Can you stack Hexarelin with Omega-3 (EPA/DHA)?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper